Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) today announced that
yesterday it received notification from the United States Food and Drug
Administration (FDA) that the Prescription Drug User Fee Act (PDUFA)
date for 99m-Tc-Tilmanocept (Lymphoseek®), has been modified
to September 10, 2012, a 90-day extension from the initial PDUFA date of
June 10th. Lymphoseek is an investigational, proprietary radioactive
tracing agent for lymphatic mapping and lymphoscintigraphy.
As part of its ongoing support of the Lymphoseek NDA review, on March
30, 2012, the Company provided as requested by the Agency, updated
chemistry, manufacturing and control information related to one of
several drug analytical assays. As this information was submitted within
the 90-day period prior to the PDUFA date, on April 2nd, FDA
at its option elected to extend the review period by 90 days to complete
a first-cycle evaluation. Neither this FDA decision nor the NDA
review-to-date has raised questions on Lymphoseek's safety or efficacy.
The PDUFA date extension does not pertain to the Company's ongoing head
and neck cancer clinical trial or to the recently announced comparative
analysis of Lymphoseek to sulfur colloid.
"We have submitted the information requested by the FDA in support of a
first-cycle review of the Lymphoseek NDA," said Mark Pykett, Navidea
President and CEO. "Our focus continues to be on supporting the FDA
review and preparing for anticipated market introduction of Lymphoseek.
All of the clinical data we have generated for Lymphoseek to date
support a clear safety and efficacy profile, which we believe holds
value to patients and their physicians."